^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L2 deletion

    i
    Other names: PDCD1LG2, Programmed Cell Death 1 Ligand 2, B7 Dendritic Cell Molecule, Programmed Death Ligand 2, Butyrophilin B7-DC, PDCD1 Ligand 2, PDCD1L2, B7-DC, CD273, PD-L2, B7DC, PDL2, PD-1-Ligand 2, CD273 Antigen, PD-1 Ligand 2, BA574F11.2, Btdc
    Entrez ID:
    80380
    Related biomarkers:
    Expression
    Others
    7ms
    Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification. (PubMed, Sci Rep)
    The LAR subtype was characterized by a high rate of PIK3CA mutation, CD274 (encodes PD-L1) and PDCD1LG2 (encodes PD-L2) deletion, and a low homologous recombination deficiency (HRD) score. The non-LAR LD TIL group was characterized by a high frequency of NOTCH2 and MYC amplification and a high HRD score.
    Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • NOTCH2 (Notch 2) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    PIK3CA mutation • HRD • MYC amplification • PD-L2 deletion • High HRD score • PD-L1 mutation